Key Insider Commits 6.4% Stake to Gilead Acquisition of Arcellx

summarizeSummary

Rami Elghandour, a significant insider, has filed an amended Schedule 13D confirming his agreement to tender his 6.4% beneficial ownership stake in Arcellx, Inc. as part of the acquisition by Gilead Sciences.

check_boxKey Events

• Insider Commits to Merger

  Rami Elghandour, a significant insider, has agreed to tender his 3,938,771 shares (6.4% beneficial ownership) in the acquisition of Arcellx by Gilead Sciences.

• Reinforces Deal Certainty

  This commitment from a major shareholder and insider provides strong support for the $7.8 billion acquisition, which was announced on February 23, 2026.

• Acquisition Terms Confirmed

  The merger consideration includes $115.00 per share in cash plus a $5.00 Contingent Value Right (CVR).

auto_awesomeAnalysis

This Schedule 13D/A from Rami Elghandour provides crucial detail regarding insider support for the recently announced acquisition of Arcellx by Gilead Sciences. Elghandour, who beneficially owns 6.4% of Arcellx's common stock, has formally agreed to tender his shares in the $7.8 billion acquisition. This commitment from a major insider reinforces the certainty of the merger, which offers shareholders $115.00 per share in cash plus a $5.00 CVR. This filing follows the initial merger announcement on February 23, 2026, and signals strong internal alignment with the deal.